Lymphocytic Leukemia: Clinical Trials

5 trials for Lymphocytic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 terminated. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 3, Recruiting 1, Terminated 1
Phase 22Completed 1, Terminated 1

Follow Lymphocytic Leukemia: new trials by email Literature Review of Lymphocytic Leukemia trials Research Report on Lymphocytic Leukemia

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
MS-553 - Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 / Phase 2TerminatedShenzhen MingSight Relin Pharmaceuticals Co., Ltd.132022-04-282024-07-18
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute142021-11-182025-12-04
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
NeoVax, Cyclophosphamide, Pembrolizumab - Lymphocytic Leukemia
Phase 1RecruitingDana-Farber Cancer Institute152021-08-182026-05-28
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ibrutinib - Lymphocytic Leukemia
Phase 1CompletedJanssen Pharmaceutical K.K.82015-07-032019-08-14
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
alemtuzumab, everolimus - Lymphocytic Leukemia
Phase 1 / Phase 2CompletedMayo Clinic282009-07-012017-09-26

Narrower conditions

Leukemia, Lymphoid (5)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neoplasms, Plasma Cell (1)

Broader conditions

Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Leukemia (4)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Leukemia, B-Cell (1)  ·  Lymphoma (1)  ·  Neoplasms by Site (1)  ·  Pathologic Processes (1)

Interventions

Alemtuzumab (1)  ·  Azacitidine (1)  ·  Cyclophosphamide (1)  ·  Everolimus (1)  ·  duvelisib (1)  ·  ibrutinib (1)  ·  pembrolizumab (1)

Sponsors

Dana-Farber Cancer Institute (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Janssen Pharmaceutical K.K. (1)  ·  Mayo Clinic (1)  ·  Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. (1)

Countries

United States (3)  ·  China (1)  ·  Japan (1)

Top investigators

Clive S. Zent, M.D. (1)  ·  Hayder Saeed, MD (1)  ·  Inhye Ahn, MD (1)  ·  Jose F. Leis, M.D. (1)  ·  Kai Zhang, MD (1)

Results publications

PMID 42545812